Stockopedia | Share Prices, Share News and Company Research

Immunodiagnostic Systems - Change to repayment schedule

Tuesday, May 10 2011 by

Immunodiagnostic Systems, the Newcastle based niche Diagnostics Company, updated investors regarding the deferred consideration from the sale of their haematology business to NASDAQ listed Escalon Medical Corporation (EMC) in January 2009.

IDS announced it has agreed to change terms of the repayment schedule from the original agreement (€4.2 million over four years), refinancing outstanding balance of €3.4 million to be payable over the next 5 years with a $50,000 combined capital and interest payment each month with a final balloon payment. Interest will continue to accrue at 7% per annum on the capital balance.

IDS sold Biocode Hycel's haematology business to EMC in January 2009 to allow the group to focus on its main activities of manual immunoassay production and the launch of the automated analyser, the IDS iSYS.


Disclaimer:  

This note was prepared by LCF Research Limited using information provided by the subject company’s management or publically available news sources. No representations are made nor warranties given (express or implied) in relation to accuracy and completeness. This document is not an invitation to invest in the subject company and does not purport to contain all the necessary information that a prospective investor might require. LCF Research Limited recommends prospective investors to conduct their own thorough independent analysis of the subject company and the information contained in this note or referred to above.


Do you like this Post?
Yes
No
0 thumbs up
0 thumbs down
Share this post with friends



Immunodiagnostic Systems Holdings plc (IDS) is engaged in manufacturing and distributing medical diagnostic products. The Company is also involved in research and development projects. The Company’s main operation is within the in vitro diagnostic (IVD) testing industry, supplying test kits to hospital and research laboratories. The Company is also engaged in the provision of immunoassay tests for the determination of vitamin D (both 25-Hydroxy and 1,25-Dihydroxy). The Company’s product include 1,25-Dihydroxy Vitamin D EIA, 1,25-Dihydroxy Vitamin D RIA, 25-Hydroxy Vitamin D EIA, 25-Hydroxy Vitamin D RIA ,Alpha CrossLaps (CTX-I) EIA, Automated IDS-iSYS System, BoneTRAP (TRAcP 5b) ELISA, Corticosterone EIA, Corticosterone HS EIA and CrossLaps for Culture (CTX-I) ELISA. more »

Share Price (AIM)
447p
Change
7.5  1.7%
P/E (fwd)
14.2
Yield (fwd)
0.7
Mkt Cap (£m)
126.7



  Is Immunodiagnostic Systems Holdings fundamentally strong or weak? Find out More »


What's your view on this thread? to Comment Now

 
 
You are feeling neutral

Use the £ sign in front of a ticker to turn £VOD into Vodafone PLC

You can track all @StockoChat comments via Twitter




Stock Picking Tutorial Centre



Stock Picking Simplified

Stockopedia takes your stock picking to the next level with cutting edge Stock Reports & Screening tools.